HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026
Genomic predictors of pathologic response to hepatic artery infusion pump chemotherapy in colorectal liver metastases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nasar Naaz F, Chou Joanne F, Datta Jashodeep, Evenhaim Maya T, Gonen Mithat, Soares Kevin C, Balachandran Vinod P, Drebin Jeffrey, Kingham T Peter, Wei Alice C, Jarnagin William R, Alessandris Remo, Shia Jinru, Cercek Andrea, O'Reilly Eileen M, Connell Louise, Kemeny Nancy, D'Angelica Michael I
Аннотация
BACKGROUND: Preoperative hepatic artery infusion pump chemotherapy (HAIP) in colorectal liver metastases (CRLM) is associated with greater pathologic response (PR). We aimed to identify genomic predictors of PR in initially unresectable (IU)-CRLM treated with preoperative HAIP.
METHODS: Three-hundred-fifty patients treated with HAIP for IU-CRLM from 2000 to 2021 were reviewed retrospectively; 96 underwent resection. Specimens were evaluated for PR and next-generation sequencing was performed. Wilcoxon rank-sum test was used to determine the association between genomic alterations and PR (continuous outcome). PR was categorized as minor (0%-74%), major (75%-99%), and complete (100%). Association between co-mutation TP53-RAS and PR was assessed using multivariable linear regression. Cox regression was used to examine the association between PR and survival.
RESULTS: Median PR was 51% in patients with TP53-RAS; 91% in those without the co-mutation (Others) (P < 0.001). TP53-RAS remained associated with lower PR (β -0.25, P < 0.001) on multivariate analysis. PR was associated with event-free survival (EFS) (HR 0.92, 95% CI: 0.85-0.98; P 0.013), not with overall survival (OS) (HR 0.94, 95% CI: 0.86-1.03).
CONCLUSION: TP53-RAS in IU-CRLM is associated with lower rates of PR to preoperative HAIP than Others. PR was associated with EFS, not with OS.
METHODS: Three-hundred-fifty patients treated with HAIP for IU-CRLM from 2000 to 2021 were reviewed retrospectively; 96 underwent resection. Specimens were evaluated for PR and next-generation sequencing was performed. Wilcoxon rank-sum test was used to determine the association between genomic alterations and PR (continuous outcome). PR was categorized as minor (0%-74%), major (75%-99%), and complete (100%). Association between co-mutation TP53-RAS and PR was assessed using multivariable linear regression. Cox regression was used to examine the association between PR and survival.
RESULTS: Median PR was 51% in patients with TP53-RAS; 91% in those without the co-mutation (Others) (P < 0.001). TP53-RAS remained associated with lower PR (β -0.25, P < 0.001) on multivariate analysis. PR was associated with event-free survival (EFS) (HR 0.92, 95% CI: 0.85-0.98; P 0.013), not with overall survival (OS) (HR 0.94, 95% CI: 0.86-1.03).
CONCLUSION: TP53-RAS in IU-CRLM is associated with lower rates of PR to preoperative HAIP than Others. PR was associated with EFS, not with OS.